Genome editing is a bimolecular technique or process that is used to make precise and effective modification to the DNA of a cell or organism. It involves the use of enzymes to cut the DNA at a specific sequence, called engineered nucleases. The characteristics of a cell or an organism can be altered by editing the genome.
Genetic modification has opened the doors for reverse genetics, linking of the DNA sequence to phenotype, and analyzing of gene function. With traditional and conventional methods becoming obsolete due to its time-consuming, inefficient, and labor-intensive characteristics, it has led to the emergence of new technologies and methodologies. Technologies such as TALEN, CRISPR /Cas9 nuclease, and ZFN boast the ability to initiate genome editing in a precise and easy manner with no limitations by the organism. These advancing technological instruments have opened new possibilities for conducting large-scale experiments and added to the market growth of gene editing. The gene editing method has attained a lot of attention in research institutions and drug development due to its capability of changing genetic mutations that can cause diseases. The global gene editing market share is forecasted to witness an impressive rise with a CAGR of 20.9% during the review period of 2023-2032.
On the other hand, constraints like strict regulatory policies and opposing public perception concerning genetic research can be detrimental to the market growth of gene editing.
Competitive Analysis
The global gene editing market players of various key players who are consistently looking to come up with new developments and innovations to further ameliorate the sector and gain a competitive edge over others. Some of the noteworthy companies profiled herein are OriGene Technologies, Inc. (U.S.), GenScript USA Inc. (U.S.), Integrated DNA Technologies, Inc. (U.S.), Lonza Group Ltd. (Switzerland), Horizon Discovery Group plc (U.K.), New England Biolabs, Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Transposagen Biopharmaceuticals, Inc. (U.S.), Sangamo Biosciences, Inc. (U.S.), and Thermo Fisher Scientific, Inc. (U.S.).
25th Feb 2019, Crispr Therapeutics AG announced the usage of its groundbreaking and highly controversial gene-editing technique CRISPR upon a patient with a debilitating blood disease. This is a highly important scientific and medical milestone for understanding the potential of this technique and its effectivity in treating serious medical conditions.
28th Jan 2019, Researchers from the Gene Editing Institute in Newark, Delaware announced the successful treatment of chemotherapy-resistant lung cancer cells with the help of the CRISPR gene-editing technique. This is monumental as this can lead to less usage of chemotherapy and can subsequently help the cancer patients lead a quality life.
Market Segmentation
The global gene editing market segmented is specified in terms of application, end-users, and methods.
By application, the market includes animal genetic engineering, gene therapy, plant genetic engineering, and microorganism’s genetic engineering.
By end-users, the market comprises pharmaceuticals, contract research organizations, and biotechnology.
By methods, the market includes TALEN, Anti-sense technology, CRISPR, ZFN, and others. The CRISPR segment holds the largest market share among the mentioned lot with close to half of the market share.
Regional Analysis
The geographical market segmentation covers regions like Asia-Pacific, the Americas, Europe, and the Middle East & Africa.
The Americas is the highest market share holder in the global geographical segmentation. The US accounts for the largest contributor to the Americas market with huge development in drug discovery research, development of the biotechnology industry, infrastructural superiority in the healthcare industry, and many other factors.
Europe closely follows the Americas with the region placing more impetus on finding better treatment solutions with investments in advancing technologies. Asia-Pacific is expected to the be fastest growing market due to increasing support from the government to proliferate the biotechnology sector. Finally, lack of technical know-how, low level of development in the biotechnology industry is limiting the growth charts of the Middle East & Africa market.
Related Report:
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian